Key Details
Price
$1.45Annual ROE
-237.22%Beta
-0.24Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
June 17, 2024Analyst ratings
Recent major analysts updates
11 Mar '22 HC Wainwright & Co.
Buy25 Aug '21 HC Wainwright & Co.
Buy16 June '20 Benchmark
Speculative Buy27 Apr '20 Ladenburg Thalmann
BuyMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Salarius Pharmaceuticals doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood
SLRX
Market Watch09 May 2023
Salarius Pharmaceuticals Inc.'s stock SLRX soared 33% in premarket trade Tuesday after the company said the U.S. Food and Drug Administration has lifted a partial clinical hold on a trial of a treatment for Ewing sarcoma, a rare and deadly form of cancer that occurs in bones or the soft tissue around bones. The treatment called seclidemstat, was being reviewed in a Phase 1/2 trial and had previously been granted Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation.
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference
SLRX
GlobeNewsWire04 April 2023
HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Wednesday, April 5th.
FAQ
- What is the primary business of Salarius Pharmaceuticals?
- What is the ticker symbol for Salarius Pharmaceuticals?
- Does Salarius Pharmaceuticals pay dividends?
- What sector is Salarius Pharmaceuticals in?
- What industry is Salarius Pharmaceuticals in?
- What country is Salarius Pharmaceuticals based in?
- When did Salarius Pharmaceuticals go public?
- Is Salarius Pharmaceuticals in the S&P 500?
- Is Salarius Pharmaceuticals in the NASDAQ 100?
- Is Salarius Pharmaceuticals in the Dow Jones?
- When was Salarius Pharmaceuticals's last earnings report?
- When does Salarius Pharmaceuticals report earnings?
- Should I buy Salarius Pharmaceuticals stock now?
What is the primary business of Salarius Pharmaceuticals?
Salarius Pharmaceuticals (SLRX) is a biotechnology company focused on developing innovative treatments for cancer. They specialize in targeted therapies that aim to improve patient outcomes and reduce side effects. Their research emphasizes precision medicine to address unmet medical needs in oncology.
What is the ticker symbol for Salarius Pharmaceuticals?
The ticker symbol for Salarius Pharmaceuticals is NASDAQ:SLRX
Does Salarius Pharmaceuticals pay dividends?
No, Salarius Pharmaceuticals does not pay dividends
What sector is Salarius Pharmaceuticals in?
Salarius Pharmaceuticals is in the Healthcare sector
What industry is Salarius Pharmaceuticals in?
Salarius Pharmaceuticals is in the Biotechnology industry
What country is Salarius Pharmaceuticals based in?
Salarius Pharmaceuticals is headquartered in United States
When did Salarius Pharmaceuticals go public?
Salarius Pharmaceuticals's initial public offering (IPO) was on 29 January 2015
Is Salarius Pharmaceuticals in the S&P 500?
No, Salarius Pharmaceuticals is not included in the S&P 500 index
Is Salarius Pharmaceuticals in the NASDAQ 100?
No, Salarius Pharmaceuticals is not included in the NASDAQ 100 index
Is Salarius Pharmaceuticals in the Dow Jones?
No, Salarius Pharmaceuticals is not included in the Dow Jones index
When was Salarius Pharmaceuticals's last earnings report?
Salarius Pharmaceuticals's most recent earnings report was on 14 November 2024
When does Salarius Pharmaceuticals report earnings?
The next expected earnings date for Salarius Pharmaceuticals is 28 February 2025
Should I buy Salarius Pharmaceuticals stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions